0000950170-24-041367.txt : 20240403 0000950170-24-041367.hdr.sgml : 20240403 20240403181400 ACCESSION NUMBER: 0000950170-24-041367 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240401 FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Campbell Bradley L CENTRAL INDEX KEY: 0001400971 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 24820619 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: (215) 921-7600 MAIL ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 ownership.xml 4 X0508 4 2024-04-01 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001400971 Campbell Bradley L 47 HULFISH STREET PRINCETON NJ 08542 true true false false President and CEO true Common Stock 2024-04-01 4 M false 7500 8.61 A 894154 D Common Stock 2024-04-01 4 S false 7500 11.6661 D 886654 D Stock Options (right to buy) 8.61 2024-04-01 4 M false 7500 0.0 D 2025-01-02 Common Stock 7500 60000 D This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.53 to $11.76 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. All of the options were fully vested and exercisable as of the transaction date. All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2023. /s/ Christian Formica, Attorney-in-Fact 2024-04-03